ImmuDyne Signs Exclusive License Agreement for Proprietary Dermatologist Backed Hair Loss Product

MT. KISCO, N.Y., Sept. 09, 2016 -- ImmuDyne (OTCQB:IMMD), a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today announced the signing of a definitive agreement with Pilaris Laboratories, LLC (“Pilaris”), for a sole and exclusive worldwide license to commercialize the patented PilarisMax line of hair loss products.

As ImmuDyne previously stated, Pilaris was founded by two prominent dermatologists, Steven D. Shapiro M.D. and Michael T. Borenstein M.D. Ph.D. after 5 years of clinical research on topical dihydrotestosterone (DHT) inhibitors. Dr. Shapiro has over 20 years of clinical experience with treating hair loss and hair transplant procedures. Dr. Borenstein holds a Ph.D. in Pharmacology and has a background in scientific research in addition to over 12 years of clinical dermatology practice.

“We are very pleased to finalize this licensing opportunity with Dr. Shapiro and Dr. Borenstein and look forward to an expected successful product launch in late 2016,” stated Mark McLaughlin, President & CEO of ImmuDyne.  “After thorough due diligence and a global competitive analysis, we believe that the Pilaris products have a better scientific foundation than any similar products currently on the market.”

“Our products have been successfully sold over the past few years via our dermatology practice, website, and friends and family,” stated Steven Shapiro M.D.  “We ’re thrilled to be passing the baton to ImmuDyne’s team of experienced marketing professionals to build what we believe will be a leading brand in the men’s and women’s hair loss category.”

Branding, positioning and business development efforts for the Pilaris product line are already underway.  A beta launch is currently planned for November 1, 2016.

About lmmuDyne

lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. The Company's products include once a day oral intake capsules as well as topical serums and creams for skin application. lmmuDyne also has developed a proprietary natural delivery technology for potential new market opportunities. All of lmmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.

Forward-Looking Statements

Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward­ looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans,"  "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

Contact:

lmmuDyne, Inc.

Mark McLaughlin: +1-914-714-8901